Your AI-Trained Oncology Knowledge Connection!

Opinion

Video

Frontline Treatments for KRAS G12C-Mutation mNSCLC

Author(s):

Joshua K. Sabari, MD,Edward B. Garon, MD, MS

Experts review the current frontline treatments for patients with KRAS G12C-mutated NSCLC.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
Durvalumab in LS-SCLC
March 17th 2025

Durvalumab Secures EU Approval for LS-SCLC After CRT

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib
March 14th 2025

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

MT-8421 in Advanced Solid Tumors | Image Credit: © Cornflakesei – stock.adobe.com
March 11th 2025

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors

NSCLC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 11th 2025

Health Canada Approves Amivantamab/Lazertinib Combo for EGFR+ Advanced NSCLC